220 related articles for article (PubMed ID: 29367449)
1. Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized double-blind phase 2 study.
Murata M; Odawara T; Hasegawa K; Iiyama S; Nakamura M; Tagawa M; Kosaka K
Neurology; 2018 Feb; 90(8):e664-e672. PubMed ID: 29367449
[TBL] [Abstract][Full Text] [Related]
2. Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: A phase 3 randomized clinical trial.
Murata M; Odawara T; Hasegawa K; Kajiwara R; Takeuchi H; Tagawa M; Kosaka K
Parkinsonism Relat Disord; 2020 Jul; 76():91-97. PubMed ID: 31982288
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Zonisamide in Dementia with Lewy Bodies Patients with Parkinsonism: A Post Hoc Analysis of Two Randomized, Double-Blind, Placebo-Controlled Trials.
Hasegawa K; Kochi K; Maruyama H; Konishi O; Toya S; Odawara T
J Alzheimers Dis; 2021; 79(2):627-637. PubMed ID: 33337365
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients With Dementia With Lewy Bodies: An Open-Label Extension of a Phase three Randomized Controlled Trial.
Odawara T; Hasegawa K; Kajiwara R; Takeuchi H; Tagawa M; Kosaka K; Murata M
Am J Geriatr Psychiatry; 2022 Mar; 30(3):314-328. PubMed ID: 34420834
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Adjunctive Therapy with Zonisamide Versus Increased Dose of Levodopa for Motor Symptoms in Patients with Dementia with Lewy Bodies: The Randomized, Controlled, Non-Inferiority DUEL Study.
Ikeda M; Mori E; Orimo S; Yamada T; Konishi O
J Alzheimers Dis; 2023; 95(1):251-264. PubMed ID: 37483001
[TBL] [Abstract][Full Text] [Related]
6. The Application of Zonisamide to Patients Suffering from Dementia with Lewy Bodies: Emerging Clinical Data.
Tousi B; Leverenz JB
Drug Des Devel Ther; 2021; 15():1811-1817. PubMed ID: 33976533
[TBL] [Abstract][Full Text] [Related]
7. Zonisamide's Efficacy and Safety on Parkinson's Disease and Dementia with Lewy Bodies: A Meta-Analysis and Systematic Review.
Kong L; Xi J; Jiang Z; Yu X; Liu H; Wang Z
Biomed Res Int; 2022; 2022():4817488. PubMed ID: 36132085
[TBL] [Abstract][Full Text] [Related]
8. The role of levodopa in the management of dementia with Lewy bodies.
Molloy S; McKeith IG; O'Brien JT; Burn DJ
J Neurol Neurosurg Psychiatry; 2005 Sep; 76(9):1200-3. PubMed ID: 16107351
[TBL] [Abstract][Full Text] [Related]
9. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial.
Emre M; Tsolaki M; Bonuccelli U; Destée A; Tolosa E; Kutzelnigg A; Ceballos-Baumann A; Zdravkovic S; Bladström A; Jones R;
Lancet Neurol; 2010 Oct; 9(10):969-77. PubMed ID: 20729148
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological Management of Dementia with Lewy Bodies.
Hershey LA; Coleman-Jackson R
Drugs Aging; 2019 Apr; 36(4):309-319. PubMed ID: 30680679
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonism.
Panza F; Lozupone M; Watling M; Imbimbo BP
Expert Opin Pharmacother; 2021 Feb; 22(3):325-337. PubMed ID: 33021110
[TBL] [Abstract][Full Text] [Related]
12. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
13. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
[TBL] [Abstract][Full Text] [Related]
14. Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies.
Fernandez HH; Trieschmann ME; Burke MA; Friedman JH
J Clin Psychiatry; 2002 Jun; 63(6):513-5. PubMed ID: 12088163
[TBL] [Abstract][Full Text] [Related]
15. Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis.
Matsunaga S; Kishi T; Iwata N
J Alzheimers Dis; 2017; 56(4):1229-1239. PubMed ID: 28157097
[TBL] [Abstract][Full Text] [Related]
16. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
[TBL] [Abstract][Full Text] [Related]
17. Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study.
Mizuno Y; Abe T; Hasegawa K; Kuno S; Kondo T; Yamamoto M; Nakashima M; Kanazawa I;
Mov Disord; 2007 Oct; 22(13):1860-5. PubMed ID: 17618525
[TBL] [Abstract][Full Text] [Related]
18. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
Oertel W; Eggert K; Pahwa R; Tanner CM; Hauser RA; Trenkwalder C; Ehret R; Azulay JP; Isaacson S; Felt L; Stempien MJ
Mov Disord; 2017 Dec; 32(12):1701-1709. PubMed ID: 28833562
[TBL] [Abstract][Full Text] [Related]
19. Improvement of both psychotic symptoms and Parkinsonism in a case of dementia with Lewy bodies by the combination therapy of risperidone and L-DOPA.
Kato K; Wada T; Kawakatsu S; Otani K
Prog Neuropsychopharmacol Biol Psychiatry; 2002 Jan; 26(1):201-3. PubMed ID: 11853113
[TBL] [Abstract][Full Text] [Related]
20. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
Pahwa R; Tanner CM; Hauser RA; Sethi K; Isaacson S; Truong D; Struck L; Ruby AE; McClure NL; Went GT; Stempien MJ
Mov Disord; 2015 May; 30(6):788-95. PubMed ID: 25650051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
